Seite - 117 - in Cancer Nanotheranostics - What Have We Learnd So Far?
Bild der Seite - 117 -
Text der Seite - 117 -
Alcantaraet al. Molecular imagingofbreast cancer
Waterton, J. C., and Pylkkanen, L. (2012). Qualification of imaging biomark-
ers for oncology drug development. Eur. J. Cancer 48, 409–415. doi:
10.1016/j.ejca.2011.11.037
Weissleder, R. (2006).Molecular imaging in cancer. Science 312, 1168–1171. doi:
10.1126/science.1125949
Yamaguchi, K., Abe, H., Newstead, G., Egashira, R., Nakazono, T., Imaizumi,
T., et al. (2014). Intratumoral heterogeneity of the distribution of kinetic
parameters in breast cancer: comparison based on the molecular subtypes
of invasive breast cancer. Breast Cancer 1–7. doi: 10.1007/s12282-013-
0512-0. [Epubaheadofprint].
Yan,C.,Wu,Y., Feng, J.,Chen,W.,Liu,X.,Hao,P., et al. (2013).Anti-alphavbeta3
antibodyguided three-steppretargetingapproachusingmagnetoliposomes for
molecular magnetic resonance imaging of breast cancer angiogenesis. Int. J.
Nanomedicine8,245–255.doi:10.2147/IJN.S38678
Zhou, Z., and Lu, Z. R. (2013). Gadolinium-based contrast agents formagnetic
resonance cancer imaging.Wiley Interdiscip. Rev.Nanomed.Nanobiotechnol.5,
1–18.doi:10.1002/wnan.1198 Conflict of Interest Statement:The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construedasapotential conflictof interest.
Received: 15 October 2014; accepted: 01 December 2014; published online: 18
December2014.
Citation:AlcantaraD, LealMP,García-Bocanegra I andGarcía-MartinML (2014)
Molecular imagingofbreastcancer:presentandfuturedirections.Front.Chem.2:112.
doi: 10.3389/fchem.2014.00112
Thisarticlewas submitted toChemicalEngineering,a sectionof the journalFrontiers
inChemistry.
Copyright © 2014 Alcantara,Leal,García-BocanegraandGarcía-Martin.This isan
open-access article distributedunder the terms of theCreativeCommonsAttribution
License (CCBY).Theuse, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are creditedand that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use,
distributionor reproduction ispermittedwhichdoesnot complywith these terms.
www.frontiersin.org December2014 |Volume2 |Article112 | 117
Cancer Nanotheranostics
What Have We Learnd So Far?
- Titel
- Cancer Nanotheranostics
- Untertitel
- What Have We Learnd So Far?
- Autoren
- João Conde
- Pedro Viana Baptista
- Jesús M. De La Fuente
- Furong Tian
- Herausgeber
- Frontiers in Chemistry
- Datum
- 2016
- Sprache
- englisch
- Lizenz
- CC BY 4.0
- ISBN
- 978-2-88919-776-7
- Abmessungen
- 21.0 x 27.7 cm
- Seiten
- 132
- Schlagwörter
- Nanomedicine, Nanoparticles, nanomaterials, Cancer, heranostics, Immunotherapy, bioimaging, Drug delivery, Gene Therapy, Phototherapy
- Kategorien
- Naturwissenschaften Chemie